127806-46-6

Basic information

• Product Name: 2-(4-Piperidinyloxy)Pyridine
• Synonyms: 2-(4-Piperidinyloxy)Pyridine;2-(4-piperidyloxy)pyridine
• CAS NO: 127806-46-6
• Molecular Formula: C₁₀H₁₄N₂O
• Molecular Weight: 178.23096
• Mol File: 127806-46-6.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-(4-Piperidinyloxy)Pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-Piperidinyloxy)Pyridine(127806-46-6)
• EPA Substance Registry System: 2-(4-Piperidinyloxy)Pyridine(127806-46-6)

Safety Data

• Hazardous Substances Data: 127806-46-6(Hazardous Substances Data)

Usage

General Description

2-(4-Piperidinyloxy)Pyridine, also known as 4-(2-Pyridyloxy)piperidine or 4-(2-Pyridyloxy)-1-azacyclohexane, is a chemical compound with the molecular formula C11H14N2O. It is a white to light yellow crystalline powder that is slightly soluble in water and soluble in organic solvents. 2-(4-Piperidinyloxy)Pyridine is often used as a building block in the synthesis of pharmaceuticals and other organic compounds. It is also known for its potential use as a ligand in catalytic processes. Additionally, 2-(4-Piperidinyloxy)Pyridine has been studied for its potential anti-inflammatory and antifungal properties. Overall, this compound has a variety of potential applications in the field of organic chemistry and drug discovery.

Upstream product

• 7379-35-3 4-chlorpyridine hydrochloride 
• 109384-19-2 t-butyl 4-hydroxy piperidine-1-carboxylate 
• 313490-35-6 tert-butyl 4-(pyridin-2-yloxy)piperidine-1-carboxylate 
• 109-04-6 2-bromo-pyridine 
• 4727-72-4 1-benzyl-4-hydroxypiperidine 
• 109-09-1 2-chloropyridine 
• 127806-47-7 1-benzyl-4-(2-pyridyloxy)piperidine 

Relevant articles and documents

Palladium-catalyzed hydrodefluorination of fluoroarenes

-

Identification of a new series of benzothiazinone derivatives with excellent antitubercular activity and improved pharmacokinetic profiles

Nitrobenzothiazinone (BTZ) is a promising scaffold with potent activity against M. tuberculosis by inhibiting decaprenylphosphoryl-beta-d-ribose 2′-oxidase (DprE1). But unfavorable durability poses a challenge to further development of this class of agents. Herein, a series of BTZs bearing a variety of different substituents at the C-2 position were designed and synthesized. Compounds were screened for their antimycobacterial activity against Mycobacterium tuberculosis H37Ra and were profiled for metabolic stability, plasma protein-binding capacity and pharmacokinetics in vivo. In general, these new BTZs containing N-piperazine, N-piperidine or N-piperidone moiety have excellent antitubercular activity and low cytotoxicity. Several of the compounds showed improved microsomal stability and lower plasma protein-binding, opening a new direction for further lead optimization. And we obtained compound 3o, which maintained good anti-tuberculosis activity (MIC = 8 nM) and presented better in vitro ADME/T and in vivo pharmacokinetic profiles than reported BTZ compound PBTZ169, which may serve as a candidate for the treatment of tuberculosis.

Sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors

This invention is directed to sulfonyl aromatic hydroxamic acid compounds and salts thereof that, inter alia, inhibit matrix metalloprotease (MMP) activity and/or aggrecanase activity. In some particularly preferred embodiments, the compound corresponds in structure to one of the following formulas: wherein W2, the R groups, and —A—R—E—Y are described in more detail in Applicants' specification. This invention also is directed to a process that comprises administering such a compound or pharmaceutically acceptable salt thereof to a host animal having a condition associated with MMP activity.